Dantrolene
- PDF / 141,411 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 106 Downloads / 167 Views
1
Dantrolene Liver dysfunction and weakness: 8 case reports One man developed liver dysfunction and seven other male patients developed generalised weakness while receiving dantrolene to relieve spasticity. One man, aged 32 years, had head injuries and multiple traumas, and was a hepatitis B surface antigen carrier. He received oral dantrolene at a dose of 75 mg/day for 6 days followed by 150 mg/day for 33 days. The dose was then increased to 400 mg/day and, 4 days later, his AST level was 121 IU/L (54 before dantrolene was started). Three days later, his AST level decreased to 57 IU/L. On the 82nd day of dantrolene treatment, his ALP and AST levels increased to 245 IU/L (167 before treatment initiation) and 85 IU/L, respectively. On the 155th day of treatment, dantrolene was withdrawn. His serum bilirubin level was >2.5 mg/dL and he was diagnosed with dantrolene-induced liver dysfunction. His serum bilirubin and ALP levels started to decrease but his AST and ALT levels remained elevated. He was lost to follow-up, but was readmitted 2 years later and his liver function test levels were normal. Seven other male patients (age range 5–62 years) who had cerebral palsy, stroke or spinal cord injury, received oral dantrolene (dose range 25–300 mg/day) for 45–1028 days and developed generalised weakness. Dantrolene was withdrawn [patient outcomes not stated]. Kim JY, et al. Safety of low-dose oral dantrolene sodium on hepatic function. Archives of Physical Medicine and Rehabilitation 92: 1359-1363, No. 9, Sep 2011. Available from: URL: http://dx.doi.org/10.1016/j.apmr.2011.04.012 - South 803061735 Korea
0114-9954/10/1374-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Reactions 22 Oct 2011 No. 1374
Data Loading...
